• CUDC-907: Dual PI3K and HDAC Workflow Guide

  2026-08-09

  CUDC-907 provides a research tool for coordinated interrogation of PI3K and histone deacetylase signaling in cancer cell models. This guide separates product-dossier specifications from workflow recommendations and is intended for controlled in vitro research, not diagnostic, therapeutic, or clinical use.

• IDO1 Inhibition and Tumor-intrinsic STAT3 Activation

  2026-08-08

  This study shows that pharmacological inhibition of IDO1 can produce a context-dependent, tumor-protective response: immune cells become more active, yet IL-6 released by infiltrating myeloid cells activates JAK2/STAT3 signaling inside tumor cells. Its single-cell analysis provides a mechanistic explanation for why IDO1 inhibition may require combination strategies that also block cytokine-driven tumor survival.

• PF-573228 FAK Inhibitor: Mechanotransduction Workflow

  2026-08-07

  PF-573228 provides a practical way to perturb FAK signaling in cancer migration, endothelial angiogenesis, and stiffness-responsive dentinogenesis assays. This workflow combines dose-aware treatment, phosphorylation readouts, matrix controls, and troubleshooting guidance to distinguish pathway inhibition from nonspecific toxicity.

• Gepotidacin for Uncomplicated Gonorrhea: Phase 2 Efficacy In

  2026-08-07

  This article reviews a pivotal phase 2 clinical study evaluating gepotidacin, a novel bacterial topoisomerase inhibitor, for the treatment of uncomplicated urogenital gonorrhea. The research demonstrates high single-dose efficacy and highlights the urgent need for alternative antibiotics amid rising resistance in Neisseria gonorrhoeae.

• DNase I (RNase-free): Enabling Precision in Translational Ge

  2026-08-06

  This article explores how DNase I (RNase-free) drives assay reproducibility and mechanistic insight in advanced RNA workflows. Blending evidence-based mechanistic guidance with real-world protocol advice, we examine the enzyme's role in translational research, highlight lessons from annexin V structural studies, and chart a strategic path for next-generation experimental design. Key differentiators include deep mechanistic rationales, a focus on chromatin and hybrid digestion, and actionable guidance for achieving DNA-free RNA in complex biological samples.

• 2'3'-cGAMP (sodium salt): Advancing STING Pathway Assays

  2026-08-06

  2'3'-cGAMP (sodium salt) unlocks sensitive, reproducible activation of the cGAS-STING axis for immunology, cancer, and antiviral research. This guide translates new mechanistic insights from hepatic injury models into actionable workflows and troubleshooting for precise innate immune modulation.

• HR-LCMS/MS Reveals Astragalus dasyanthus as a Source of Glab

  2026-08-05

  This study introduces a streamlined HR-LCMS/MS-based dereplication protocol to rapidly identify autophagy-inducing compounds in plant extracts, demonstrating its effectiveness by discovering Astragalus dasyanthus as a novel producer of glabrol. These findings enable more efficient high-throughput screening of natural autophagy inducers relevant to mitochondrial and metabolic research.

• Etoposide (VP-16): Data-Driven Solutions for Robust DNA Dama

  2026-08-05

  This article addresses persistent laboratory challenges in apoptosis induction and DNA damage assays, guiding biomedical researchers on how 'Etoposide (VP-16)' (SKU A1971) delivers reproducible, data-backed solutions. With real-world scenario Q&As and protocol insights, it demonstrates why this APExBIO-supplied topoisomerase II inhibitor remains a cornerstone for cancer cell research.

• Cefazedone (Refosporen): Mechanism, Efficacy, and Protocols

  2026-08-04

  Cefazedone (Refosporen) is a first-generation cephalosporin antibiotic with robust β-lactamase-resistant activity against both Gram-positive and Gram-negative bacteria. Its primary mode of action is the inhibition of bacterial cell wall synthesis, and it demonstrates consistent efficacy in established in vitro and in vivo protocols. This article details its biological rationale, mechanism, clinical benchmarks, and workflow integration for antibacterial testing.

• NPT1-Mediated Renal Transport of Faropenem Sodium and PAH: M

  2026-08-04

  This study provides the first molecular evidence that human NPT1, an apical membrane transporter in renal proximal tubules, mediates the transport of p-aminohippuric acid (PAH) and several organic anions, including faropenem. Through expression in HEK293 cells, the research clarifies NPT1's substrate profile and advances understanding of organic anion secretion, with implications for antibiotic disposition and pharmacokinetic modeling.

• Transmission Dynamics of Carbapenemase Genes in CREC in Guan

  2026-08-03

  This study provides a comprehensive molecular and epidemiological analysis of carbapenemase-encoding genes in carbapenem-resistant Enterobacter cloacae (CREC) across eight teaching hospitals in Guangdong, China. The findings highlight the predominance of plasmid-mediated blaNDM-1, extensive multidrug resistance, and the mobility of resistance genes, informing strategies for surveillance and experimental resistance modeling.

• Oral Faropenem Sodium: Resistance Risks and Treatment Effect

  2026-08-03

  This article reviews the implications of oral faropenem sodium use for antimicrobial resistance (AMR) and clinical effectiveness, focusing on its increasing adoption, mechanism, and regulatory landscape. The reference study highlights concerns regarding overuse, cross-resistance with carbapenems, and the need for stewardship, especially in high-consumption regions.

• Isorhamnetin: Enhancing Oocyte Maturation via PI3K/Akt Activ

  2026-08-02

  Isorhamnetin, a distinctive flavonoid, unlocks new precision in oxidative stress and apoptosis research by modulating PI3K/Akt pathways. This guide details advanced workflows, troubleshooting strategies, and practical insights for deploying Isorhamnetin in reproductive cell biology assays.

• Lenalidomide (CC-5013): Next-Generation Immunomodulation in

  2026-08-01

  Explore how Lenalidomide (CC-5013) transforms multiple myeloma research through multi-modal immune system activation and epigenetic synergy. Discover unique insights into assay design and mechanistic innovation supported by recent breakthroughs.

• Targeting Plasmodium Aminopeptidases: Phebestin’s Antiplasmo

  2026-07-31

  The referenced study identifies phebestin, a bestatin-related aminopeptidase inhibitor, as a potent antiplasmodial agent with nanomolar efficacy against both chloroquine-sensitive and -resistant strains of Plasmodium falciparum. The research demonstrates phebestin’s ability to inhibit parasite growth across all intraerythrocytic stages and reduce parasitemia in vivo, providing a mechanistically distinct lead for antimalarial drug development.

443 records 8/30 page Previous Next First page 上5页 678910 下5页 Last page